BioLife Solutions Management
Management criteria checks 2/4
BioLife Solutions' CEO is Rod de Greef, appointed in Oct 2023, has a tenure of 1.33 years. total yearly compensation is $6.39M, comprised of 3.1% salary and 96.9% bonuses, including company stock and options. directly owns 0.26% of the company’s shares, worth $3.24M. The average tenure of the management team and the board of directors is 1.3 years and 16.3 years respectively.
Key information
Rod de Greef
Chief executive officer
US$6.4m
Total compensation
| CEO salary percentage | 3.1% |
| CEO tenure | 1.3yrs |
| CEO ownership | 0.3% |
| Management average tenure | 1.3yrs |
| Board average tenure | 16.3yrs |
Recent management updates
Recent updates
Is BioLife Solutions (NASDAQ:BLFS) Weighed On By Its Debt Load?
Jan 24
BioLife Solutions, Inc.'s (NASDAQ:BLFS) Shares Climb 27% But Its Business Is Yet to Catch Up
Dec 15Is It Too Late To Consider Buying BioLife Solutions, Inc. (NASDAQ:BLFS)?
Nov 30Analysts Have Lowered Expectations For BioLife Solutions, Inc. (NASDAQ:BLFS) After Its Latest Results
Nov 15Is BioLife Solutions (NASDAQ:BLFS) Using Debt Sensibly?
Oct 25Is There An Opportunity With BioLife Solutions, Inc.'s (NASDAQ:BLFS) 20% Undervaluation?
Sep 14Why BioLife Solutions, Inc. (NASDAQ:BLFS) Could Be Worth Watching
Aug 30Investors Appear Satisfied With BioLife Solutions, Inc.'s (NASDAQ:BLFS) Prospects As Shares Rocket 28%
Aug 14BioLife Solutions (NASDAQ:BLFS) Has Debt But No Earnings; Should You Worry?
Jun 20A Look At The Fair Value Of BioLife Solutions, Inc. (NASDAQ:BLFS)
Jun 05Revenues Not Telling The Story For BioLife Solutions, Inc. (NASDAQ:BLFS) After Shares Rise 25%
May 14Broker Revenue Forecasts For BioLife Solutions, Inc. (NASDAQ:BLFS) Are Surging Higher
May 13Should You Investigate BioLife Solutions, Inc. (NASDAQ:BLFS) At US$19.54?
May 11Does BioLife Solutions (NASDAQ:BLFS) Have A Healthy Balance Sheet?
Mar 12BioLife Solutions, Inc.'s (NASDAQ:BLFS) Intrinsic Value Is Potentially 64% Above Its Share Price
Feb 19BioLife Solutions, Inc.'s (NASDAQ:BLFS) Share Price Matching Investor Opinion
Dec 19Downgrade: Here's How Analysts See BioLife Solutions, Inc. (NASDAQ:BLFS) Performing In The Near Term
Aug 17Is BioLife Solutions (NASDAQ:BLFS) Weighed On By Its Debt Load?
Aug 11Health Check: How Prudently Does BioLife Solutions (NASDAQ:BLFS) Use Debt?
May 06Should You Think About Buying BioLife Solutions, Inc. (NASDAQ:BLFS) Now?
Feb 22Health Check: How Prudently Does BioLife Solutions (NASDAQ:BLFS) Use Debt?
Jan 10Is There An Opportunity With BioLife Solutions, Inc.'s (NASDAQ:BLFS) 20% Undervaluation?
Dec 10CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$49m |
| Jun 30 2024 | n/a | n/a | -US$64m |
| Mar 31 2024 | n/a | n/a | -US$62m |
| Dec 31 2023 | US$6m | US$199k | -US$66m |
| Sep 30 2023 | n/a | n/a | -US$79m |
| Jun 30 2023 | n/a | n/a | -US$74m |
| Mar 31 2023 | n/a | n/a | -US$141m |
| Dec 31 2022 | US$2m | US$450k | -US$140m |
| Sep 30 2022 | n/a | n/a | -US$106m |
| Jun 30 2022 | n/a | n/a | -US$96m |
| Mar 31 2022 | n/a | n/a | -US$15m |
| Dec 31 2021 | US$1m | US$412k | -US$9m |
| Sep 30 2021 | n/a | n/a | US$5m |
| Jun 30 2021 | n/a | n/a | US$4m |
| Mar 31 2021 | n/a | n/a | -US$20m |
| Dec 31 2020 | US$3m | US$391k | US$2m |
| Sep 30 2020 | n/a | n/a | US$7m |
| Jun 30 2020 | n/a | n/a | US$16m |
| Mar 31 2020 | n/a | n/a | US$39m |
| Dec 31 2019 | US$1m | US$403k | -US$2m |
| Sep 30 2019 | n/a | n/a | -US$32m |
| Jun 30 2019 | n/a | n/a | -US$39m |
| Mar 31 2019 | n/a | n/a | -US$44m |
| Dec 31 2018 | US$490k | US$350k | -US$25m |
Compensation vs Market: Rod's total compensation ($USD6.39M) is about average for companies of similar size in the US market ($USD5.31M).
Compensation vs Earnings: Rod's compensation has increased whilst the company is unprofitable.
CEO
Rod de Greef (64 yo)
1.3yrs
Tenure
US$6,387,586
Compensation
Mr. Roderick de Greef, also known as Rod, serves as Director of BioLife Solutions, Inc. since January 03, 2023 and serves as its Chief Executive Officer & Chairman since October 20, 2023. He had been Presi...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman | 1.3yrs | US$6.39m | 0.26% $ 3.2m | |
| Chief Financial Officer | 3.3yrs | US$1.70m | 0.26% $ 3.3m | |
| Chief Quality & Operations Officer | 1.1yrs | US$1.12m | 0.34% $ 4.3m | |
| Chairman of Scientific Advisory Board | 5.2yrs | US$1.35m | 0.57% $ 7.2m | |
| Chief Technology Officer | less than a year | no data | 0.011% $ 138.9k | |
| Chief Commercial Officer | less than a year | US$734.45k | 0.23% $ 2.9m | |
| Chief Human Resources Officer | 4.1yrs | no data | 0.13% $ 1.6m |
1.3yrs
Average Tenure
53.5yo
Average Age
Experienced Management: BLFS's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman | 2.1yrs | US$6.39m | 0.26% $ 3.2m | |
| Chairman of Scientific Advisory Board | no data | US$1.35m | 0.57% $ 7.2m | |
| Member of Scientific Advisory Board | 18.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 17.4yrs | no data | no data | |
| Member of Scientific Advisory Board | 18.3yrs | no data | no data | |
| Member of the Scientific Advisory Board | no data | US$284.00k | no data | |
| Member of Scientific Advisory Board | 17.4yrs | no data | no data | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Independent Lead Director | 3.8yrs | US$269.17k | 0.039% $ 496.4k | |
| Independent Director | 3.3yrs | US$250.00k | 0.064% $ 814.9k | |
| Member of Scientific Advisory Board | 16.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 13.1yrs | no data | no data |
16.3yrs
Average Tenure
58.5yo
Average Age
Experienced Board: BLFS's board of directors are seasoned and experienced ( 16.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/02 04:35 |
| End of Day Share Price | 2025/01/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
BioLife Solutions, Inc. is covered by 20 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robert Wasserman | Benchmark Company |
| George Zavoico | B. Riley Securities, Inc. |
| Matthew Hewitt | Craig-Hallum Capital Group LLC |